Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

• DOI: 10.1126/science.274.5291.1363
• Publication Date: 2002-07-27T09:45:50Z
• Authors: M. Hahne; D. Rimoldi; M. Schröter; P. Romero; M. Schreier; L. E. French; P. Schneider; T. Bornand; A. Fontana; D. Lienard; J.-C. Cerottini; J. Tschopp
• Keywords: Fas ligand; Immune privilege

Malignant melanoma accounts for most of the increasing mortality from skin cancer. Melanoma cells were found to express Fas (also called Apo-1 or CD95) ligand (FasL). In metastatic lesions, Fas-expressing T cell infiltrates proximal FasL+ tumor cells. vitro, apoptosis Fas-sensitive target occurred upon incubation with cells; and in vivo, injection mouse mice led rapid formation. contrast, tumorigenesis was delayed Fas-deficient lpr mutant which immune effector cannot be killed by FasL. Thus, FasL may contribute privilege tumors.